Drug developer D-Pharm on Scrip Award shortlist

IDF procurement of Chinese drones raises concerns

The company was nominated for "Best company in an emerging market".

Drug development company D-Pharm Ltd. (TASE: DPRM) is one of five companies on the shortlist for the "Best company in an emerging market" Scrip Award.

The 6th annual Scrip Awards, whose winners will be announced on November 4th in London, are considered a significant and prestigious ranking in the biotech and pharmaceutical industries.

"I'd like to see Teva in India and China"

D-Pharm reports positive heart trial results

Clal Biotech streams NIS 15.7m to D Pharm

FDA approves D-Pharm Phase III protocol in stroke study

D-Pharm treats first stoke patient in Phase III trial

The other four companies on the shortlist are India's Aanjaneya Lifecare, Argentina's Bio Sidus, South Korea's CrystalGenomics, and India's Dr. Reddy's Laboratories.

The nomination recognizes D-Pharm's achievements in the last 12 months. These include commencement of the MACSI Phase III study with DP-b99 in acute ischemic stroke patients under IND and SPA; the company�s successful listing on the Tel Aviv Stock Exchange; and licensing of the marketing rights for DP-b99 in China.

Published by Globes [online], Israel business news - www.globes-online.com - on September 14, 2010